KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Receivables - Other (2019 - 2023)

Historic Receivables - Other for Royalty Pharma (RPRX) over the last 5 years, with Q4 2023 value amounting to $14.2 million.

  • Royalty Pharma's Receivables - Other fell 1537.73% to $14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $14.2 million, marking a year-over-year decrease of 1537.73%. This contributed to the annual value of $14.2 million for FY2023, which is 1537.73% down from last year.
  • According to the latest figures from Q4 2023, Royalty Pharma's Receivables - Other is $14.2 million, which was down 1537.73% from $16.4 million recorded in Q3 2023.
  • Over the past 5 years, Royalty Pharma's Receivables - Other peaked at $59.7 million during Q3 2021, and registered a low of $14.2 million during Q4 2023.
  • In the last 5 years, Royalty Pharma's Receivables - Other had a median value of $32.3 million in 2020 and averaged $29.8 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first surged by 8428.58% in 2021, then crashed by 7366.28% in 2022.
  • Royalty Pharma's Receivables - Other (Quarter) stood at $33.5 million in 2019, then dropped by 1.1% to $33.2 million in 2020, then soared by 60.72% to $53.3 million in 2021, then plummeted by 68.42% to $16.8 million in 2022, then decreased by 15.38% to $14.2 million in 2023.
  • Its Receivables - Other stands at $14.2 million for Q4 2023, versus $16.4 million for Q3 2023 and $16.4 million for Q2 2023.